Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with

Karen Ferrell and Edward A. Kangas Expand VIVUS’ Board to Nine Members CAMPBELL, Calif. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that Karen Ferrell and Edward A. Kangas have been appointed to VIVUS’ board of

CAMPBELL, Calif. , Oct. 26, 2018 (GLOBE NEWSWIRE) -- VIVUS , Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2018 after the market close on Thursday, November 1, 2018. The company will host a conference call beginning

CAMPBELL, Calif. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that

CAMPBELL, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today that it has regained full compliance with Nasdaq

CAMPBELL, Calif. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. , (NASDAQ: VVUS), a biopharmaceutical company that develops and commercializes novel therapeutic products to address unmet medical needs in human health, announced today that it will make a presentation at the Fourth Annual Robins

-Fundraising event at AT&T Stadium on September 22 supports the Dallas-Fort Worth chapter of the Cystic Fibrosis Foundation - CAMPBELL, Calif. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that it is supporting the

CAMPBELL, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that the Company’s stockholders approved a reverse stock split. Effective September 10, 2018 , the Company will enact a 1-for-10 reverse stock split of its

-Retrospective analysis presented at the 34 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - CAMPBELL, Calif. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, has reported encouraging data from a

CAMPBELL, Calif. , Aug. 22, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that